关键词: 寄生虫感染, 抗体, 单克隆, 免疫应答, 生物制品

Abstract:

Recently, biologics targeting type 2 inflammatory pathways, such as interleukin-4 (IL-4)/IL-13, IL-5, and immunoglobulin E (IgE), have become effective approaches for treatment of type 2 inflammatory diseases. Nevertheless, these biologics not only precisely suppress excessive inflammatory responses, but also interfere with the body’s capability to fight against parasitic infections, thereby increasing the risk of infection. Although such adverse events are relatively rare, their potential associations have been paid attention in clinical practices. Currently, there is still a lack of systematic understanding regarding the exact mechanisms underlying parasitic infections induced by biologics with diverse targets, the characteristics of high-risk populations, and clinical management strategies. This article aims to provide a review of these aspects, so as to provide insights into clinical practices.

Key words: Parasitic infection, Antibody, Monoclonal, Immune response, Biological product